IL258638B2 - Antibodies with polyvalent variable segment - Google Patents

Antibodies with polyvalent variable segment

Info

Publication number
IL258638B2
IL258638B2 IL258638A IL25863818A IL258638B2 IL 258638 B2 IL258638 B2 IL 258638B2 IL 258638 A IL258638 A IL 258638A IL 25863818 A IL25863818 A IL 25863818A IL 258638 B2 IL258638 B2 IL 258638B2
Authority
IL
Israel
Prior art keywords
polypeptide
variable domains
pair
unit
variable
Prior art date
Application number
IL258638A
Other languages
English (en)
Hebrew (he)
Other versions
IL258638B (en
IL258638A (en
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of IL258638A publication Critical patent/IL258638A/en
Publication of IL258638B publication Critical patent/IL258638B/en
Publication of IL258638B2 publication Critical patent/IL258638B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL258638A 2015-10-13 2016-10-13 Antibodies with polyvalent variable segment IL258638B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15189665.1A EP3156417A1 (en) 2015-10-13 2015-10-13 Multivalent fv antibodies
PCT/EP2016/074642 WO2017064221A1 (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Publications (3)

Publication Number Publication Date
IL258638A IL258638A (en) 2018-06-28
IL258638B IL258638B (en) 2022-12-01
IL258638B2 true IL258638B2 (en) 2023-04-01

Family

ID=54325413

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258638A IL258638B2 (en) 2015-10-13 2016-10-13 Antibodies with polyvalent variable segment

Country Status (13)

Country Link
US (1) US11572415B2 (https=)
EP (2) EP3156417A1 (https=)
JP (1) JP6936497B2 (https=)
KR (1) KR20180057720A (https=)
CN (1) CN108473577A (https=)
AU (1) AU2016336866B2 (https=)
BR (1) BR112018007445A2 (https=)
CA (1) CA3001765A1 (https=)
IL (1) IL258638B2 (https=)
MX (1) MX2018004547A (https=)
SG (2) SG10202004094VA (https=)
WO (1) WO2017064221A1 (https=)
ZA (1) ZA201802543B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293435B1 (en) 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
BR112020018492A2 (pt) 2018-03-14 2020-12-29 Affimed Gmbh Proteína de ligação ao antígeno egfr/cd16 biespecífica
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
CA3095373A1 (en) * 2018-04-13 2019-10-17 Affimed Gmbh Nk cell engaging antibody fusion constructs
CN112384243A (zh) * 2018-04-17 2021-02-19 英温拉公司 三价三特异性抗体构建体
HRP20240821T1 (hr) 2018-08-27 2024-09-27 Affimed Gmbh Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
JP7592712B2 (ja) * 2019-11-06 2024-12-02 システィミューン， インク． ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
TWI908779B (zh) * 2020-03-17 2025-12-21 美商西雅圖免疫公司 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
US20250277024A1 (en) * 2020-12-03 2025-09-04 Amgen Inc. Molecules with multiple binding domains
US20250074996A1 (en) * 2021-02-19 2025-03-06 Innovent Biologics (Suzhou) Co., Ltd. ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
TW202330594A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
US20230272069A1 (en) * 2022-02-28 2023-08-31 Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135345A1 (en) * 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
ATE387458T1 (de) * 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
CA2410551A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
EP1293514B1 (en) * 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
WO2003057829A2 (en) 2001-12-26 2003-07-17 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from vh and vl domains
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US20100150927A1 (en) * 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
DK3725807T3 (da) * 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
WO2014106015A2 (en) 2012-12-28 2014-07-03 Abbvie, Inc. Multivalent binding protein compositions
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
IL293435B1 (en) * 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135345A1 (en) * 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLAUDIA C. ROSKOPF ET AL,, T CELL-RECRUITING TRIPLEBODY 19-3-19 MEDIATES SERIAL LYSIS OF MALIGNANT B-LYMPHOID CELLS BY A SINGLE T CELL, 23 July 2014 (2014-07-23) *
KIPRIYANOV S M ET AL,, BISPECIFIC TANDEM DIABODY FOR TUMOR THERAPY WITH IMPROVED ANTIGEN BINDING AND PHARMACOKINETICS, 15 August 1999 (1999-08-15) *
SCHUBERT INGO ET AL,, A DUAL-TARGETING TRIPLEBODY MEDIATES PREFERENTIAL REDIRECTED LYSIS OF ANTIGEN DOUBLE-POSITIVE OVER SINGLE-POSITIVE LEUKEMIC CELLS., 31 January 2014 (2014-01-31) *
SCHUBERT INGO ET AL,, A SINGLE-CHAIN TRIPLEBODY WITH SPECIFICITY FOR CD19 AND CD33 MEDIATES EFFECTIVE LYSIS OF MIXED LINEAGE LEUKEMIA CELLS BY DUAL TARGETING., 31 December 2011 (2011-12-31) *
UWE REUSCH ET AL,, A NOVEL TETRAVALENT BISPECIFIC TANDAB (CD30/CD16A) EFFICIENTLY RECRUITS NK CELLS FOR THE LYSIS OF CD30 + TUMOR CELLS, 26 March 2014 (2014-03-26) *

Also Published As

Publication number Publication date
MX2018004547A (es) 2018-11-09
CA3001765A1 (en) 2017-04-20
RU2018126966A (ru) 2020-02-10
EP3362478A1 (en) 2018-08-22
AU2016336866B2 (en) 2023-05-25
US11572415B2 (en) 2023-02-07
IL258638B (en) 2022-12-01
CN108473577A (zh) 2018-08-31
ZA201802543B (en) 2020-01-29
WO2017064221A1 (en) 2017-04-20
BR112018007445A2 (pt) 2019-12-10
KR20180057720A (ko) 2018-05-30
SG10202004094VA (en) 2020-05-28
JP6936497B2 (ja) 2021-09-15
EP3156417A1 (en) 2017-04-19
IL258638A (en) 2018-06-28
JP2018537415A (ja) 2018-12-20
RU2018126966A3 (https=) 2020-04-20
SG11201803083XA (en) 2018-05-30
AU2016336866A1 (en) 2018-05-10
US20190040155A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
US11572415B2 (en) Multivalent FV antibodies
US20220048994A1 (en) Trifunctional antigen-binding molecule
US20240294647A1 (en) Uses of nk cell engaging antibody fusion constructs for treatments
US20240425616A1 (en) Bispecific t cell activating antigen binding molecules
CN110382539B (zh) 用于cd16a定向的nk细胞结合的串联双抗体
EP3600407A1 (en) Improved antigen binding receptors
KR20200026995A (ko) 향상된 이중 특이성 폴리펩티드 분자
RU2785766C9 (ru) Мультивалентные fv-антитела
RU2785766C2 (ru) Мультивалентные fv-антитела
CA3210650A1 (en) Bispecific antibodies enhancing cell mediated immune responses
US20250312452A1 (en) Antibody targeting claudin18.2 and its applications
HK1260025A1 (en) Multivalent fv antibodies
NZ721138B2 (en) Bispecific t cell activating antigen binding molecules
NZ721138A (en) Bispecific t cell activating antigen binding molecules